A
Anne L. Thomas
Researcher at University of Leicester
Publications - 105
Citations - 3881
Anne L. Thomas is an academic researcher from University of Leicester. The author has contributed to research in topics: Cancer & Medicine. The author has an hindex of 28, co-authored 93 publications receiving 3394 citations. Previous affiliations of Anne L. Thomas include University Hospitals of Leicester NHS Trust & Leicester Royal Infirmary.
Papers
More filters
Journal ArticleDOI
Dynamic Contrast-Enhanced Magnetic Resonance Imaging As a Biomarker for the Pharmacological Response of PTK787/ZK 222584, an Inhibitor of the Vascular Endothelial Growth Factor Receptor Tyrosine Kinases, in Patients With Advanced Colorectal Cancer and Liver Metastases: Results From Two Phase I Studies
Bruno Morgan,Anne L. Thomas,Joachim Drevs,Juergen Hennig,Martin Büchert,Asvina Jivan,Mark A. Horsfield,K. Mross,H. A. Ball,Lucy Lee,William Mietlowski,Stefan Fuxius,Clemens Unger,Kenneth J. O'Byrne,Andrew Henry,Graham R. Cherryman,Dirk Laurent,Margaret Dugan,Dieter Marmé,William P. Steward +19 more
TL;DR: In this article, the authors evaluated the pharmacodynamic effects of PTK/ZK by assessing changes in contrastenhancement parameters of metastatic liver lesions using dynamic contrastenhanced magnetic resonance imaging (DCE-MRI) in patients with advanced colorectal cancer treated in two ongoing, dose-escalating phase I studies.
Journal ArticleDOI
Panitumumab versus cetuximab in patients with chemotherapy-refractory wild-type KRAS exon 2 metastatic colorectal cancer (ASPECCT): a randomised, multicentre, open-label, non-inferiority phase 3 study.
Timothy J. Price,Marc Peeters,Tae Won Kim,Jin Li,Stefano Cascinu,Paul Ruff,Atilli Satya Suresh,Anne L. Thomas,Sergei Tjulandin,Kathy Zhang,Swaminathan Murugappan,Roger Sidhu +11 more
TL;DR: It is shown that panitumumab is non-inferior to cetuximab and that these agents provide similar overall survival benefit in this population of patients, and small but meaningful differences in the rate of grade 3-4 infusion reactions and differences in dose scheduling can guide physician choice of anti-EGFR treatment.
Journal ArticleDOI
Phase I Study of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of PTK787/ZK 222584 Administered Twice Daily in Patients With Advanced Cancer
Anne L. Thomas,Bruno Morgan,Mark A. Horsfield,Anthony Higginson,Andrea C. Kay,Lucy Lee,Eric Masson,Marie Puccio-Pick,Dirk Laurent,William P. Steward +9 more
TL;DR: DCE-MRI and pharmacokinetic data indicate that the maximum-tolerated oral dose of PTK/ZK >/= 1,000 mg total daily dose is the biologically active dose.
Journal ArticleDOI
High-Level Clonal FGFR Amplification and Response to FGFR Inhibition in a Translational Clinical Trial
Alex Pearson,Elizabeth C Smyth,Irina S. Babina,Maria Teresa Herrera-Abreu,Noelia Tarazona,Clare Peckitt,Elaine Kilgour,Neil R. Smith,Catherine Geh,Claire Rooney,Ros Cutts,James Campbell,Jian Ning,Kerry Fenwick,Amanda Swain,Gina Brown,Sue Chua,Anne L. Thomas,Stephen R. D. Johnston,Mazhar Ajaz,Katherine Anne Sumpter,Angela Gillbanks,David Watkins,Ian Chau,Sanjay Popat,David Cunningham,Nicholas C. Turner,Nicholas C. Turner +27 more
TL;DR: Using cell lines and patient-derived xenograft models, it is shown that high-level FGFR2 amplification initiates a distinct oncogene addiction phenotype, characterized byFGFR2-mediated transactivation of alternative receptor kinases, bringing PI3K/mTOR signaling under FGFR control.
Journal ArticleDOI
A phase I, multicenter, open-label, first-in-human, dose-escalation study of the oral smoothened inhibitor sonidegib (LDE225) in patients with advanced solid tumors
Jordi Rodon,Hussein Tawbi,Anne L. Thomas,Ronald G. Stoller,Christian P. Turtschi,José Baselga,John Sarantopoulos,Devalingam Mahalingam,Yaping Shou,Melissa A. Moles,Lin Yang,Camille Granvil,Eunju Hurh,Kristine Rose,Dereck Amakye,Reinhard Dummer,Alain C. Mita +16 more
TL;DR: Sonidegib has an acceptable safety profile in patients with advanced solid tumors and exhibits antitumor activity in advanced BCC and relapsed medulloblastoma, both of which are strongly associated with activated hedgehog pathway, as determined by gene expression.